Adam
Elsesser

The lawyer who learned to vacuum the brain

Adam Elsesser is the rare CEO who runs a publicly traded medical device company without a medical degree, an engineering degree, or an MBA. He has a JD. He spent the back end of the 1990s as a partner at Shartsis Friese in San Francisco, doing commercial real estate work, until a college friend named Arani Bose - a neurointerventionalist with a stack of sketches - asked him to help build a stent that could go inside the brain. Elsesser said yes. He has been saying yes to neurovascular problems ever since.

The first company, Smart Therapeutics, shipped the first intracranial stent. Boston Scientific bought it in 2002. Elsesser stayed on to run the SMART division for three years, learned how a giant medtech actually moves a product through hospitals, and walked out the door in 2004 with Bose to start over. They named the new company Penumbra. The medical meaning - the rim of brain tissue around a stroke that is starving but not yet dead, the part you can still save - is the entire product thesis. The other meaning, the half-light, the willingness to work in the shadow of louder competitors, is the culture.

For most of the next decade Penumbra was a quiet Alameda outfit doing one strange thing: aspiration. While Stryker and Medtronic were winning the room with stent retrievers - little wire baskets that grab a clot and pull it out - Penumbra was building catheters that simply suck the clot out, like a straw at the bottom of a milkshake. The technique was not fashionable. The clinical evidence had to be earned hospital by hospital, neurointerventionalist by neurointerventionalist. Elsesser was patient about it in a way that doesn't read well in a pitch deck. He kept hiring engineers, kept iterating the catheter, kept publishing data.

The company went public in 2015. Elsesser took the Chairman seat the same January. By the early 2020s aspiration was no longer a contrarian bet - it had become the default first-line approach for a large category of large-vessel occlusion strokes, with most physicians combining aspiration and stent retrieval in the same procedure. Penumbra had pulled the rest of the field toward its idea.

Then came the platform decisions. The Indigo system pushed aspiration into peripheral and pulmonary clots, opening a market that wasn't supposed to exist when Penumbra started. Lightning Flash, launched in 2024, wired computer-vision-style intelligence into the pump itself - sensing whether the catheter tip was on a clot or sucking blood, and modulating accordingly. It moved the company out of the "clever catheter" category and into the "thinking system" category. Revenue crossed a billion dollars. Margins followed. The stock price followed the margins.

On January 15, 2026, Boston Scientific announced it was buying Penumbra for $14.5 billion in cash and stock - $374 a share. Elsesser, who could have taken the cash, elected to take the BSX stock for all of his Penumbra shares. He is slated to join the Boston Scientific board when the deal closes. There is a circularity to this that should not be lost on anyone: Elsesser sold his first company to Boston Scientific in 2002, walked, built a competitor, and came back twenty-four years later with the asset BSX wanted in order to re-enter the neurovascular market it had exited a decade earlier.

He still talks about the work the same way. Devices, evidence, physician adoption, patient outcomes. There is no chapter where Elsesser becomes a thought-leader on stage at Davos. He is, by most accounts of the people who have worked with him, the same operator at $1.4 billion in revenue that he was at $14 million - long-horizon, engineer-friendly, allergic to slogans, very interested in what happens inside a hospital catheter lab at 2 a.m. when the on-call neurointerventionalist needs to remove a clot from a brain that is currently dying. Penumbra exists to make those minutes go faster. Elsesser exists to make sure the company keeps existing for that purpose.

The strange specific that explains him: he runs a company whose name is the part of the brain you can still save, which is also a description of his core market - the salvageable middle, the place where minutes turn into outcomes - which is also, if you squint, a description of his career, sliding into medtech in his early thirties because a friend asked, then refusing to leave for twenty-two years.

What he actually does all day

Elsesser describes the job in plain terms in interviews: hire device engineers, fund clinical trials, manage manufacturing, talk to physicians. The org chart at Penumbra is short and the engineering culture is loud. The company makes most of its catheters in-house in California rather than outsourcing - a choice that costs more and is harder to scale and that, in 2020, when supply chains broke, turned out to be the difference between shipping and not shipping.

He has a stated preference, repeated across investor calls, for "uncertainty over risk." The distinction is real and very much an Elsesser one: uncertainty means you don't know how big the upside is yet. Risk means you might lose money you already have. He will spend years on something whose payoff isn't legible to a quarterly model. He will not chase a category where the product looks like everyone else's.

Penumbra is a two-person founding story. Elsesser met Dr. Arani Bose in college; Bose, a neurointerventionalist, brought the medical insight, and Elsesser brought the operating company. They have started two medical device companies together (Smart Therapeutics, then Penumbra), sold one to Boston Scientific, and now sold the second.

The relationship is unusually durable. Most cofounder pairs don't make it through one venture, much less twenty-six years across two. The division of labor explains some of it: Bose has the device intuition, Elsesser runs the company. Neither steps on the other's lane.